Eisai R&d Management Co., Ltd.

Alkermes Pharma Ireland Limited

Nuvalent, Inc.

Immunogen, Inc.

Baudouin Gerard

John JianShi Wang

Julius F Remenar

Guo Zhu Zheng

Thomas Andrew Wynn

Brian M Aquila

Todd Bosanac

Yoshihiko Kotake

Gregg F Keaney

Lewis D Pennington

Kazunobu Kira

Parcharee Tivitmahaisoon

Sudeep Prajapati

Norio Murai

Hoan Huynh

Markus Haeberlein

Demetri Theodore Moustakas

Roman A Valiulin

Ingo Andreas Mugge

Xiang Liu

Satoshi Nagao

Masayuki Miyano

Kenzo Arai

Nicholas C Gearhart

Regina Mikie Kanada Sonobe

Atsushi Endo

Peter G Smith

Silvia Buonamici

Lihua Yu

Ermira Pazolli

Joshua Courtney Horan

Kian Huat Lim

Eunice Sun Park

Michael P Thomas

Betty Chan

Michael Louis Miller

Ming-Hong Hao

Manami Shizuka

Dominic J Reynolds

Scot Richard Mente

Richard A Silva

Matthew D Shair

Andrew Cook

Marta Nevalainen

Henry Efrem Pelish

Arani Chanda

Jason T Lowe

James Palacino

Shelby Ellery

Anupong Tangpeerachaikul

Sibao Chen

Lisa A Marcaurelle

David James Pearson

Benjamin Stephen Lane

Jason T Kropp

Christopher G F Cooper

Morgan Welzel O'shea

Tuoping Luo

Kristin Lynne Andrews

Yuting Sun

Regina Mikie Kanada Sonabe

Regina Kanada Sonobe

Sundeep Prajapati

Provided herein are solid forms comprising a compound of formula (I), or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of synthesizing a compound of formula (I), pharmaceutical compositions comprising the same, and methods of treating, preventing, and managing various disorders using the compositions provided herein.

Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds

Disclosed are amino-substituted heteroaromatic compounds such as a compound of Formula (I): pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof. Also disclosed are methods of treating or preventing cancer using the amino-substituted heteroaromatic compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.

Amino-substituted heteroaryls for treating cancers with EGFR mutations

The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.

Certain pladienolide compounds and methods of use

The present invention provides compounds useful for the treatment of opioid dependence, alcohol dependence, alcohol use disorder, or the prevention of relapse to opioid dependence in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.

Thiophene compounds for long-acting injectable compositions and related methods

Thienothiophene compounds for long-acting injectable compositions and related methods

Naphthylenyl compounds for long-acting injectable compositions and related methods

The present disclosure provides a novel solid state form of pladienolide pyridine compounds having Formula I, compositions comprising at least one such solid state form, and methods of preparation and use and the same. The novel solid state form of pladienolide pyridine compounds may be useful in the treatment of cancer, such as, for example, cancers in which agents that target the spliceosome and mutations therein are known to be useful. 

Crystalline form of (2S,3S,6S,7R,10R,E)-7,10-dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(piridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl-4-methylpiperazine-1-carboxylate and methods of use thereof

The present invention provides novel pladienolide pyridine compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful.

Pladienolide pyridine compounds and methods of use

Growing community of inventors

Arlington, MA, United States of America

Baudouin Gerard